BioPorto A/S (THOXF)

0.3100 -0.1245 (-28.66%) At close: 11:49AM EDT

BioPorto A/S

Tuborg Havnevej 15, st.
Ground Floor
Hellerup 2900
Denmark
45 45 29 00 00
https://bioporto.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 27

Description

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.

Corporate Governance

BioPorto A/S’s ISS Governance QualityScore as of May 1, 2024 is 3. The pillar scores are Audit: 4; Board: 1; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.